Research programme: solid tumour therapeutics - Incuron

Drug Profile

Research programme: solid tumour therapeutics - Incuron

Alternative Names: CBL 0175; CBLC100 series; Curaxins

Latest Information Update: 09 Mar 2015

Price : $50

At a glance

  • Originator Cleveland BioLabs
  • Class Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA intercalators; NF-kappa B inhibitors; SSRP1 protein inhibitors; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 09 Mar 2015 Preclinical development is underway in USA
  • 02 Mar 2015 Solid tumour therapeutics are covered by patent protection in USA
  • 30 Apr 2012 A lead candidate, CBLC 137, enters into clinical development in Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top